Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$303000.0.

  • Cytosorbents' Change in Receivables rose 7709.75% to -$303000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $531419.0, marking a year-over-year increase of 9585.71%. This contributed to the annual value of $1.7 million for FY2024, which is 60045.07% up from last year.
  • Per Cytosorbents' latest filing, its Change in Receivables stood at -$303000.0 for Q3 2025, which was up 7709.75% from -$336889.0 recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Change in Receivables peaked at $1.4 million during Q2 2023, and registered a low of -$1.3 million during Q3 2024.
  • In the last 5 years, Cytosorbents' Change in Receivables had a median value of $28046.0 in 2021 and averaged $119677.8.
  • In the last 5 years, Cytosorbents' Change in Receivables skyrocketed by 75271.34% in 2022 and then plummeted by 70170.55% in 2023.
  • Cytosorbents' Change in Receivables (Quarter) stood at -$698683.0 in 2021, then surged by 161.32% to $428400.0 in 2022, then crashed by 183.49% to -$357670.0 in 2023, then surged by 405.15% to $1.1 million in 2024, then crashed by 127.76% to -$303000.0 in 2025.
  • Its Change in Receivables stands at -$303000.0 for Q3 2025, versus -$336889.0 for Q2 2025 and $79889.0 for Q1 2025.